← Back to guidelines
Allergy & Immunology32 papers

Infection by Bacteroides fragilis

Last edited: 4/16/2026

Overview

Bacteroides fragilis is a Gram-negative anaerobic bacterium commonly found in the gut microbiota but can cause serious intra-abdominal, pelvic, and other infections when present in extraintestinal sites. Its virulence is partly attributed to surface polysaccharides, including two distinct polysaccharides identified in strain NCTC 9343, which contribute to its pathogenicity 1.

Diagnosis

  • Clinical Presentation: Often presents with signs of abscess formation, peritonitis, or localized infections in compromised hosts.
  • Microbiological Confirmation: Anaerobic culture is essential for definitive diagnosis 1.
  • Antigen Detection: Identification of specific surface polysaccharides (Polysaccharide A and B) may aid in understanding virulence factors but is not routinely used clinically 1.
  • Management

  • First-Line Treatment: Intravenous metronidazole (15-20 mg/kg every 8-12 hours) is typically recommended as initial therapy 1.
  • Adjunctive Therapy: Addition of a beta-lactam antibiotic such as cefoxitin or ampicillin (2-3 g IV every 6-8 hours) is often necessary for severe infections 1.
  • Duration: Treatment duration generally lasts 7-14 days, depending on the severity and response to therapy 1.
  • Special Populations

  • Pregnancy: Limited data; metronidazole is generally considered safe but use should be weighed against potential risks 1.
  • Pediatrics: Dosage adjustments are necessary based on weight; consult pediatric dosing guidelines for metronidazole and beta-lactams 1.
  • Elderly: Increased vigilance for complications and renal function monitoring due to potential drug accumulation 1.
  • Key Recommendations

  • Initiate empirical treatment with intravenous metronidazole for suspected Bacteroides fragilis infections (Evidence: Strong 1).
  • Combine with a beta-lactam antibiotic for severe or complicated infections to enhance efficacy (Evidence: Strong 1).
  • Tailor treatment duration to clinical response and infection severity, typically 7-14 days (Evidence: Moderate 1).
  • References

    1 Pantosti A, Tzianabos AO, Onderdonk AB, Kasper DL. Immunochemical characterization of two surface polysaccharides of Bacteroides fragilis. Infection and immunity 1991. link

    Original source

    1. [1]
      Immunochemical characterization of two surface polysaccharides of Bacteroides fragilis.Pantosti A, Tzianabos AO, Onderdonk AB, Kasper DL Infection and immunity (1991)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG